We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Vasomotor Symptoms
MedXY News
EnglishTag

Vasomotor Symptoms

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study
CardiologySWAN studyRace

Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study

By MedXY|Sep 13, 2026

Initiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 years

Integrative Medicine Approaches for Menopause: Evidence-Based Nonhormonal Strategies for Symptom Management
newsintegrative medicine
nonhormonal therapy

Integrative Medicine Approaches for Menopause: Evidence-Based Nonhormonal Strategies for Symptom Management

By MedXY|Aug 18, 2026

This article reviews evidence-based integrative medicine approaches for menopause, including lifestyle, mind-body therapies, nutrition, botanicals, and acupuncture, emphasizing nonhormonal options for symptom relief and health optimization.

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found
OB/GYN & Women's Healthhot flushesnight sweats

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found

By MedXY|Aug 18, 2026

A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.

Hormone Therapy for Hot Flashes: Safe and Effective for Women 50–59, Harm Signals After Age 70 — New WHI Secondary Analysis Clarifies Cardiovascular Risk by Age
Cardiologycardiovascular diseaseMenopausal Hormone Therapy

Hormone Therapy for Hot Flashes: Safe and Effective for Women 50–59, Harm Signals After Age 70 — New WHI Secondary Analysis Clarifies Cardiovascular Risk by Age

By MedXY|Nov 18, 2025

A WHI secondary analysis finds that oral conjugated estrogens (with or without MPA) relieve vasomotor symptoms in women 50–59 without clear ASCVD harm, but starting HT in women ≥70 is associated with increased atherosclerotic cardiovascular

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Clinical UpdatesElinzanetantMenopause

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

By MedXY|Nov 13, 2025

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
newsElinzanetantMenopause

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

By MedXY|Nov 13, 2025

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes
OB/GYN & Women's HealthElinzanetantMenopause

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY|Oct 24, 2025

Bayer’s Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable

Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study
OB/GYN & Women's HealthMenopauseperimenopause

Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study

By MedXY|Oct 4, 2025

The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reprod

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis
OB/GYN & Women's Healthbreast cancerElinzanetant

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY|Oct 4, 2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials
AIdigital therapeuticsMenopause

Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials

By MedXY|Oct 4, 2025

This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.

FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms
newsElinzanetantFDA

FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms

By MedXY|Sep 30, 2025

The FDA delays its review of Bayer’s elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities